- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 27.03. | More revamp at Bayer as it axes 90 at its U.S. headquarters in New Jersey | ||
| 27.03. | Spending on diabetes, weight loss TV spots climbs as drugmakers wrestle for share | ||
| 26.03. | Bristol Myers Squibb cuts hundreds of Mirati staffers months after closing $5.8B buyout | ||
| 26.03. | Merck scores key FDA approval for pulmonary arterial hypertension drug Winrevair | ||
| 26.03. | Amgen, facing potential Enbrel price cap in Colorado, takes state's new drug affordability board to court | ||
| 26.03. | MysteryVibe wishes NYC 'Happy Menopause' with 1st US billboards to show a sex toy | ||
| 26.03. | Big Pharma CEOs gather in Beijing to show continued interest in China, offer policy advice | ||
| 26.03. | With biopharma industry tuned in, Supreme Court hears arguments around medication abortion | ||
| 26.03. | Bluebird's Lyfgenia launch gains traction but shares tumble with report of accounting errors | ||
| 26.03. | Caring Cross, Brazil's Fiocruz team up to produce cell and gene therapies at a fraction of their cost in the US | ||
| 25.03. | In banner year, Lilly rewards CEO David Ricks with 24% boost in total pay to $26.6M | ||
| 25.03. | SK Life Science marks Purple Day for epilepsy awareness by highlighting patient support programs | ||
| 25.03. | Invivyd's COVID prophylactic scores FDA emergency nod for people with compromised immune systems | ||
| 25.03. | With Merck's key PAH approval on tap, Johnson & Johnson wins nod for combo tablet | ||
| 25.03. | AstraZeneca's rare disease unit overcomes FDA snub to expand Ultomiris in NMOSD | ||
| 25.03. | Novo Nordisk, Actylis ink pact to supply antiseptic in parts of Europe | ||
| 25.03. | FTC weighs in on Teva's asthma inhaler litigation against Amneal amid far-reaching patent crackdown | ||
| 25.03. | BioNTech hit with 'notice of default' from NIH in COVID-19 vaccine royalty dispute | ||
| 22.03. | Novo Nordisk closes in on EU approval for its once-weekly insulin Awiqli | ||
| 22.03. | Lilly CEO reaffirms commitment to Chinese market amid US threat against local biotechs | ||
| 22.03. | Italfarmaco nabs FDA approval for new nonsteroidal Duchenne muscular dystrophy med, teeing up sparring match with Sarepta | ||
| 21.03. | In his swan song at Bristol Myers Squibb, former CEO Giovanni Caforio pulled down $19.7M | ||
| 21.03. | Merck KGaA's MilliporeSigma drops €300M on Korean biologics plant with plans to create 300 new jobs | ||
| 21.03. | Catalent lays off 130 staffers at massive Indiana facility being sold to Novo Nordisk | ||
| 21.03. | BioTek reMEDys calls for awareness of safe bleeding disorder drug use |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
